



GICOM EXPERIENCE IN GCIG

ADRIANA CHÁVEZ- BLANCO, DVM

Harmonisation & Operations GICOM

Co-ordinator GCIG CCRN, Latin América

Gynecologic Cancer InterGroup



Grupo Mexicano de Investigación en Cáncer de Ovario y Tumores Ginecológicos, A.C. (GICOM)

A Non-profit group created in 2007 in response of the need of having a multidisciplinary group dedicated to the study and research of the gynaecological cancer in México, with the main purpose of transmitting the knowledge of this disease as well as its prevention, timely detection and treatment among the Mexican women.

Chair: Dolores Gallardo Rincón,MD.

GICIG Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



General Overview

GICOM contributes to:

- Establishing standard therapies for gynaecological cancers that guarantee an improvement in the quality and duration of life of women with this condition.
 - National Consensus
- The development of strategies for the prevention and early detection of the ovarian cancer and gynaecological tumours
 - Academic activities
 - Alliance with Advocacy Groups, Universities, Institutions, etc.
 - Active participation in the management of public policies management (Government) for the acceptance of the ovarian and endometrial cancer as a public health problem.

GICIG Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



GICOM and GCIG

GICOM joined to the Gynecological Cancer Intergroup (GCIG) in 2007

Promotes and Coordinates the development of clinical, basic and translational Research within the gynaecological cancer area as well as the inter-institutional cooperation in clinical research.

- Working with Cancer Centers and Universities in the country
- Promoting High quality

GCIG Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



Why GCIG?

➤ Same Vision

- *“...Improving quality and duration of life for women with gynecologic cancers..”*

Positive Experience

➤ Fosters International Cooperation and Clinical Research

- Common purpose
- Expertise
- Respect

Gynecologic Cancer InterGroup



Positive Experience (cont.)

- Cross-cultural diversities
- Improvement in quality and site staff performance
- Management of the Regulations, Local and International
- Harmonisation of Clinical Operations
- Complexity of International Academic trials
- Re-education

Gynecologic Cancer InterGroup



Positive Experience (cont.)

- Industry and National Cancer Program Support
- Mentoring
- Educational Activities
 - Symposia, Educational Workshops, Brainstorming, etc.

❖ GCIG CCRN

Cervical Cancer: Educational Symposium and Clinical Trials Workshop

Jan 28-29, 2017, México City, México

GCIG Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



- Current GICOM participation in GCIG Clinical Trials:
 - **ICON8-** An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer
 - *Follow-up*
 - **INTERLACE-** A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer.
 - *On going*

Gynecologic Cancer InterGroup



THANK YOU !!

GCIg Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



GCIg Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



GCIIG Education Symposium, November 2017, Vienna

Gynecologic Cancer InterGroup



GCIIG Education Symposium, November 2017, Vienna